• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Middleton, G
    Palmer, D
    Greenhalf, W
    Ghaneh, P
    Jackson, R
    Cox, T
    Evans, A
    Shaw, V
    Wadsley, J
    Valle, Juan W
    Propper, D
    Wasan, H
    Falk, S
    Cunningham, D
    Coxon, F
    Ross, P
    Madhusudan, S
    Wadd, N
    Corrie, P
    Hickish, T
    Costello, E
    Campbell, F
    Rawcliffe, C
    Neoptolemos, J
    Show allShow less
    Affiliation
    University of Birmingham, Edgbaston, Birmingham, UK
    Issue Date
    2017-03-01
    
    Metadata
    Show full item record
    Abstract
    Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer.
    Citation
    Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. 2017 Lancet Oncol
    Journal
    The Lancet Oncology
    URI
    http://hdl.handle.net/10541/620214
    DOI
    10.1016/S1470-2045(17)30084-0
    PubMed ID
    28259610
    Type
    Article
    Language
    en
    ISSN
    1474-5488
    ae974a485f413a2113503eed53cd6c53
    10.1016/S1470-2045(17)30084-0
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    • Authors: Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V, German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators
    • Issue date: 2021 Feb
    • Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
    • Authors: Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW
    • Issue date: 2015 Jul
    • Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
    • Authors: Dorman K, Boeck S, Caca K, Reichert M, Ettrich TJ, Oettle H, Waidmann O, Modest DP, Müller L, Michl P, Kanzler S, Pink D, Reinacher-Schick A, Geißler M, Pelz H, Kunzmann V, Held S, Schichtl T, Heinemann V, Kullmann F
    • Issue date: 2024 Oct
    • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Authors: Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Investigators
    • Issue date: 2020 Jan
    • Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
    • Authors: Grande E, Arranz JÁ, De Santis M, Bamias A, Kikuchi E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, O'Donnell PH, Kalebasty AR, Ye D, Mariathasan S, Bene-Tchaleu F, Bernhard S, Lee C, Davis ID, Galsky MD
    • Issue date: 2024 Jan
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.